AgriLabs Awarded Patent for DNA Vaccines Delivery System
The receipt of a U.S. patent for its ENABL adjuvant technology and its use as a delivery system for the DNA vaccines it is developing is a major step forward for AgriLabs.
“DNA vaccines offer tremendous promise in terms of efficacy, safety, and convenience, and ENABL technology is unique in its ability to help realize that potential,” says Steve Schram, president and CEO of AgriLabs.
These vaccines, he explains, can be tools in the fight against emerging animal diseases because they offer a far faster response than conventional vaccines. And because DNA vaccines don’t expose the animals being treated to disease-producing organisms, there is no risk of a modified pathogen mutating back to a virulent form. DNA vaccines also enable you to differentiate between infected and vaccinated animals.
“ENABL adjuvants feature a lipid/polymer matrix that allows for more efficient delivery of both DNA and traditional vaccines to target cells,” says Dr. Tim Miller, AgriLabs chief scientific officer. “This means we have an expandable platform that can address issues such as reduced number of doses for DNA vaccines, which makes them economically viable options.”
Since the DNA vaccines being developed are stable in refrigeration and at room temperature, transport and storage will not be an issue.
Initially, the company plans to focus on securing USDA approval for its DNA vaccine platform in poultry and swine. AgriLabs will develop vaccines for those species based on the platform, as well as cattle and other food animals.
“Our DNA platform, including ENABL adjuvant technology, represents the next generation of biological innovation in animal health,” Schram says. “We’re pleased to be recognized with the granting of a patent for this significant step forward.”
The company is looking for commercial partners to license the platform for companion and food animals outside the U.S.
Learn more by visiting agrilabs.com.